belantamab mafodotin
gsk
['belantamab']
the belantamab vs pom/dex trial is another myeloma trial in which both control arm/intervention arm suffered. fit patients could have been better served by triplets rather than control arm, and intervention arm suffered ocular toxicity- all for q not even relevant. #asco23 
Cancer doctor at @huntsmancancer with interest in myeloma, supportive care, end of life, cost-effective/evidence-based care and med-ed. No COI. Views own.